UNSPSC 51373430: Chlorpheniramine/hydrocodone/menthol/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373430 Chlorpheniramine/hydrocodone/menthol/pseudoephedrine is a Commodity code that nominally describes a specific combination pharmaceutical product, but recent state and local solicitations tagged with this code show minimal alignment with the code's actual scope. The two recent opportunities posted under this code—a Seminole County, Florida naloxone and drug deactivation systems purchase and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic multi-source pharmaceutical RFP—do not target the specific drug combination the code names. Instead, they reflect broader pharmaceutical and opioid-response procurement activity that state health agencies, counties, and cooperative purchasing vehicles are conducting. The solicitations show issuing bodies including county health departments and state procurement offices administering multistate cooperative frameworks, but the mismatch between the code's nominal scope and the actual work being bought suggests this code may be applied inconsistently or as a default classifier for pharmaceutical-adjacent procurements that do not fit a more specific code.

Geographic activity appears concentrated in Florida and Minnesota based on recent postings, though the MMCAP RFP signals participation across multiple states including Oregon. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building and a July 26, 2023 response deadline (note: posted date and response deadline are inconsistent in the source). MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, requesting comprehensive pricing for generic pharmaceuticals and OTC products from manufacturers, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. The MMCAP procurement requires compliance with cGMP and the Drug Supply Chain Security Act, pricing through three authorized wholesalers, and a two-year contract term. Given the code's apparent misclassification in recent activity, firms should verify coding before making pursue decisions.